PharmaVigilant Expands Inspire EDC System to Support Multiple Languages
PharmaVigilant
, a clinical trial technology provider, has enhanced its InSpire Electronic Data Capture (EDC) system to support multiple languages for the management of even more complex, large-scale global clinical trials. InSpire now supports Italian, Spanish, Portuguese, French, German, Dutch, English, Danish, Swedish, Norwegian, and Icelandic as well as Malay and Swahili languages, with additional languages to be added in a multi-phased approach. These updates allow sponsors to easily build multilingual studies, and support data entry and reporting in any of these languages for easier and more compliant data capture.
PharmaVigilant’s InSpire EDC system addresses the evolving complexities of clinical development by bringing together technologies that support the needs of both the industry and end-users throughout the entire clinical development process. With PharmaVigilant’s integrated approach, InSpire eliminates the need for separate systems and ensures fast study start up and data lock by providing, role-specific work flow tools empowering sites to enter and review data with minimal training. Now available in multiple languages, the system features customized study tabs with real-time information on enrollment, data entry, data monitoring, sign off and data lock.
PharmaVigilant offers a full suite of clinical trial technology offerings including InSpire EDC, I-Warehouse, I-Builder, I-Vault electronic Trial Master File (eTMF), I-Vault remote Source Document Verification (rSDV), study administration and PaySite - an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 14 countries across North America, South America, Europe, Asia and Australia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
